The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Pom/dex combinations as salvage for myeloma R/R to dara
Annamaria Brioli, MD, Universitätsklinikum Jena, Jena, Germany, discusses the use of pomalidomide and dexamethasone combinations as salvage therapy for multiple myeloma patients relapsed and/or refractory to daratumumab. This area of research is particularly pertinent, with the use of daratumumab for the treatment of myeloma becoming increasingly widespread. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Annamaria Brioli, MD, receives research founding from Celgene and Honoraria from Janssen, Celgene, Takeda, Amgen and GSK.
